Xvivo Perfusion AB (publ) reports Q2 results
Seeking Alpha ·
Xvivo Perfusion AB (publ) press release ( XVIPY ): Q2 Revenue of $239M. Thoracic sales increased by 53 percent in local currencies and by 52 percent excluding revenue from heart trials. Abdominal sales increased by 26 percent in local currencies.
DYAX Investor Sentiment
Bullish (Long) 49% · Bearish (Short) 51%
414 participants
Related News
- Apple Lawsuit Threatens OpenAI's Hardware Push as 400+ Ex-Apple Staff Join
- 1844 Resources launches non‑brokered private placement to raise up to $1M
- AAPL Stock Slips — OpenAI Says It Sees No ‘Evidence’ That Apple Lawsuit Has Merit
- Bank Stocks Diverge Post-Earnings. Citi Drops, While Goldman Hits Fresh Record.
- Advanced Micro Devices, Inc. (AMD) Stock Surges as Goldman Sees Big Earnings Coming
- Microsoft Corporation (MSFT) to Cut 4,800 Jobs